Elektronisk udgave - Sundhedsstyrelsen

90
❖ FRANCE: Rachid Salmi, MD, PhD; Charlotte Huet, MD. Université
Victor Segalen Bordeaux II, Bordeaux. Luc Noel, MD.
Centre Hospitalier de Versailles, Versailles.
❖ DENMARK: Helga Sigmund, MSc. Danish Institute for Health
Technology Assessment, Copenhagen.
❖ AUSTRALIA: David Henry, MD; Carla Treloar, PhD. University
of Newcastle. Katherine McGrath, MD; Kim Henderson. Hunter
Area Pathology Service, Newcastle.
More information about the group and its publications is available
on the ISPOT-website: www.lri.ca/programs/ceu/ispot/.
Funding:
Dr. Laupacis received the First Fellowship from the International
Society of Technology Assessment in Health Care, funded by the
PPP Medical Trust, United Kingdom in order to do this study. The
Ottawa Coordinating Centre has received funding from Janssen
Ortho Inc, Canada, the Australian Group from the National Health
and Medical Research Council and the Hunter Area Pathology Services,
the Scottish Group from the Scottish National Blood Transfusion
Service and the Clinical Resources & Audit Group of the
Scottish Health Service, the French Group from Haemonetics
France, Ortho Diagnostics France and University Segalen Bordeaux
2, the group from the United States from the Baxter Healthcare
Corporation Biotech Group and the Emory Center for Clinical
Evaluation Sciences, and the Danish group from The Pharmacy
Foundation of 1991.
8.2 Deltagerpanelet ved ISPOTs danske ekspertmøde
Panelet blev sammensat efter henvendelse til følgende selskaber og
enheder:
Dansk Selskab for Anæstesiologi og Intensiv Medicin
Morten Mygind Brinkløv, Bent Gymoese Jørgensen, Erling Anker-Møller
Dansk Karkirurgisk Selskab
Eskild Henneberg
Dansk Kirurgisk Selskab
Claus Bisgaard
Dansk Ortopædisk Selskab
Søren Solgaard, Ole Ovesen